×
About 12,038 results

Another Approval Bites the Dust; Booze-Cancer Link Off Radar; Lung Ca Surveillance
https://www.medpagetoday.com/hematologyoncology/othercancers/102029

Dec 2nd, 2022 - Roche/Genentech will voluntarily withdraw accelerated approval of atezolizumab (Tecentriq) for advanced bladder cancer. The move follows the failure of a phase III trial to show a benefit in overall survival. Cryotherapy proved more effective than thermal ablation of small renal tumors, according to a retrospective comparison of the two strategies. (Journal of Urology) A survey of 3,865 U.S. ad...

New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia
https://www.medpagetoday.com/hematologyoncology/leukemia/102019

Dec 2nd, 2022 - The FDA approved the IDH1 inhibitor olutasidenib (Rezlidhia) for relapsed or refractory acute myeloid leukemia (AML). The approved indication stipulates use of olutasidenib in relapsed/refractory AML associated with an IDH1 mutation. The FDA also approved the Abbott RealTime IDH1 Assay as a companion diagnostic to select patients for olutasidenib. "Rezlidhia is a novel, non-intensive monotherap...

Year in Review: Non-Hodgkin Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/102027

Dec 2nd, 2022 - Developments in non-Hodgkin lymphoma in 2022 were punctuated by new indications for chimeric antigen receptor (CAR) T-cell therapies, the FDA's crackdown on PI3K inhibitors, and a new warning about breast implant-related lymphomas. Indications Come and Indications Go The FDA stayed busy in 2022, with three different CAR T-cell therapies gaining new indications in non-Hodgkin lymphoma. Lisocabta...

Year in Review: Diffuse Large B-Cell Lymphoma
https://www.medpagetoday.com/hematologyoncology/lymphoma/101996

Dec 1st, 2022 - Second-line treatment for diffuse large B-cell lymphoma (DLBCL) got a big boost in 2022 with new indications for a pair of chimeric antigen receptor (CAR) T-cell therapies, while an antibody-drug conjugate moved one step closer to shaking up treatment in the first-line setting. CAR-T Products Move to Second-Line In April, axicabtagene ciloleucel (axi-cel; Yescarta) became the first CAR T-cell t...

Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancer
https://www.medpagetoday.com/hematologyoncology/prostatecancer/101967

Nov 29th, 2022 - Metastasis-directed therapy (MDT) in selected patients with recurrent oligometastatic prostate cancer led to PSA responses in a majority of patients and delayed initiation of hormonal therapy by 18 months, a retrospective study showed. Overall, 77 of 124 patients had PSA declines of more than 50% with surgery or stereotactic body radiation therapy (SBRT). In particular, surgery led to PSA respo...

Lung Screening Saves Lives; Clues to Hyperprogression; Bacteria Foil Immunotherapy
https://www.medpagetoday.com/hematologyoncology/lungcancer/101912

Nov 25th, 2022 - Diagnosis of early-stage lung cancer with low-dose CT screening was associated with significant improvement in long-term survival. (Mount Sinai, Radiological Society of North America) Researchers have discovered how cancer immunotherapy sometimes causes paradoxical tumor hyperprogression and identified a potential mechanism to prevent it. (Science Translational Medicine) Continuing its expansio...

FDA OKs First Gene Therapy for Hemophilia B
https://www.medpagetoday.com/hematologyoncology/hemophilia/101882

Nov 22nd, 2022 - The FDA on Tuesday approved the first gene therapy for treating hemophilia B, a genetic bleeding disorder resulting from missing or insufficient levels of factor IX. Etranacogene dezaparvovec (Hemgenix) is indicated for adults with the condition who currently use factor IX prophylaxis therapy for blood clotting, those who have or have had life-threatening hemorrhage, or those who have repeated ...

Exercise During Chemo Shows Benefits for Cardiorespiratory Fitness
https://www.medpagetoday.com/hematologyoncology/chemotherapy/101856

Nov 21st, 2022 - Physical exercise during chemotherapy is not only safe, but helps to prevent declines in cardiorespiratory fitness and to facilitate a faster return to normal daily activities, compared with waiting until after chemotherapy is completed, the prospective ACT trial showed. Among 266 patients with mostly breast, testicular, or colon cancer who were randomized to a 24-week exercise intervention eit...

Despite Guidelines, Many Older Women Are Still Screened for Cervical Cancer
https://www.medpagetoday.com/hematologyoncology/cervicalcancer/101844

Nov 21st, 2022 - Despite recommendations against cervical cancer screening for average-risk women ages 65 and older, more than 1.3 million women in the Medicare fee-for-service population underwent screening in 2019, with significant costs, a cross-sectional analysis showed. Although the overall proportion of these women who received at least one cytology or human papillomavirus (HPV) test decreased from 1999 (...

Year in Review: Hemophilia
https://www.medpagetoday.com/hematologyoncology/hemophilia/101803

Nov 17th, 2022 - Over the past year, momentum for gene therapy in hemophilia has continued to build -- a trend suggesting it will be available in the clinic sooner rather than later. After three decades of talking about gene therapy and two decades of clinical trials in hemophilia, "we've now been able to move towards a safety benefit ratio that I think is going to lead to commercial availability of a gene ther...

FDA OKs First Antibody-Drug Conjugate for Platinum-Resistant Ovarian Cancer
https://www.medpagetoday.com/hematologyoncology/ovariancancer/101748

Nov 15th, 2022 - The FDA granted accelerated approval for the antibody-drug conjugate (ADC) mirvetuximab soravtansine (Elahere) for folate receptor α (FRα)-positive platinum-resistant ovarian cancer. The action makes mirvetuximab the first ADC with an indication for platinum-resistant ovarian cancer. The indication includes patients who have received one to three prior systemic therapies for platinum-resistant ...

Oral, Hormone-Free Med Reduces Hot Flashes in Breast Cancer Patients
https://www.medpagetoday.com/hematologyoncology/breastcancer/101713

Nov 11th, 2022 - A novel, non-hormonal oral drug was effective in reducing hot flashes and night sweats in women taking oral adjuvant endocrine therapy after breast cancer, according to results from a phase II study. After 28 days of treatment, patients taking the investigational therapy, Q-122, had a significantly greater mean percentage change from baseline in the Vasomotor Symptom Severity Score of moderate ...

More Racial Cancer Disparities; Potential Pharma Bankruptcy; HPV Vax Efficacy
https://www.medpagetoday.com/hematologyoncology/othercancers/101676

Nov 10th, 2022 - American Indian and Alaska Native individuals have a substantially higher cancer mortality despite cancer incidence similar to other racial/ethnic groups in the U.S. (American Cancer Society) Non-Hispanic Black patients were less likely to receive complete guideline-recommended care for ovarian cancer even after adjustment for access-to-care issues. (National Comprehensive Cancer Network) A lay...

Myeloma Patients Who Relapse After CAR T-Cell Therapy Have Options
https://www.medpagetoday.com/hematologyoncology/myeloma/101588

Nov 4th, 2022 - Patients with multiple myeloma who relapse after treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested. Among 79 patients who were given a total of 237 salvage treatments, median overall survival (OS) from the date of relapse post-CAR T-cell therapy was 17.9 months (...

The High Cost of Cancer; Bone Fracture Risk in Survivors; MRI Gear Shortage
https://www.medpagetoday.com/hematologyoncology/othercancers/101580

Nov 4th, 2022 - The annual price of newly launched cancer drugs has increased 53% over the last 5 years, according to a report by U.S. Rep. Katie Porter (D-Calif.). (Reuters) A survey of large employers found that cancer has become the top driver of employer healthcare costs, with 13% reporting that they have seen more late-stage cancers impacting their workforce, and 44% predicting an increase in cancer diagn...

Treatment De-Escalation Shows Promise in Testicular Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/101567

Nov 3rd, 2022 - A reduced dose of chemotherapy and involved node radiotherapy (INRT) may be viable for patients with stage IIA or IIB seminoma of the testis, results from a phase II study suggested. In a group of 116 patients, a single-dose of carboplatin along with de-escalated INRT yielded a 3-year progression-free survival (PFS) rate of 93.7% (90% CI 88.5-96.6), reported Alexandros Papachristofilou, MD, of ...

Lenalidomide-Induced Second Cancer Risk Limited to Multiple Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/101551

Nov 2nd, 2022 - Lenalidomide (Revlimid)-induced second primary malignancies appear to be limited to patients with multiple myeloma, according to a systematic review and meta-analysis. While there was no significant increase in the risk of second primary malignancies associated with lenalidomide across all cancers (risk ratio [RR] 1.16, 95% CI 0.96-1.39), there was an increased risk associated with the immunomo...

Study: U.S. Chemo Regimen for Ewing Sarcoma Should Be International Standard
https://www.medpagetoday.com/hematologyoncology/othercancers/101533

Nov 1st, 2022 - The standard chemotherapy regimen used to treat patients with newly diagnosed Ewing sarcoma in the U.S. was more effective, less toxic, and shorter in duration than the previous standard used in Europe, a phase III randomized trial showed. Over a median follow-up of 47 months, the 3-year event-free survival (EFS) rate among patients treated with the U.S. standard of care was 67% compared with 6...

Year in Review: Multiple Myeloma
https://www.medpagetoday.com/hematologyoncology/myeloma/101517

Nov 1st, 2022 - Developments in multiple myeloma over the past year were marked by the approvals of a first-in-class drug for relapsed or refractory disease and a second chimeric antigen receptor (CAR) T-cell therapy, as well as some encouraging news and disappointments on the research front. New Approvals Last month, the FDA granted accelerated approval to teclistamab (Tecvayli) for the treatment of triple-cl...

Year in Review: Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/101523

Nov 1st, 2022 - As 2022 draws to a close, breast cancer specialists and their patients can look back on a year that produced a game-changing therapeutic development and several incremental improvements in clinical management. Most observers acknowledged the emergence of trastuzumab deruxtecan (T-DXd, Enhertu) as the first-ever targeted option for HER2-low breast cancer as a practice-changing event. About 15-20...